Randomized Portion (Part 2) of REFRαME-O1 Trial of luvelta for patients with platinum-resistant ovarian cancer (PROC) initiated May 7, 2024
Ph 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept + Keytruda in Patients with Untreated HPV-Mediated Oropharyngeal Cancer initiated May 7, 2024
First Patients Dosed in Two Ph 1 Trials of REM-422 of Adenoid Cystic Carcinoma (ACC) and AML/MDS May 7, 2024
First Patient Dosed in trial Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC May 7, 2024
Ph 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of OS as 1L Treatment in Patients With HER2+ve Advanced Gastric/GEJ Adenocarcinoma May 7, 2024
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer May 7, 2024
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology May 7, 2024
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib May 7, 2024
Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines based on Activation Lethality platform May 7, 2024
Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Ph 2 Trial in Advanced Ovarian Cancer May 7, 2024
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline May 7, 2024
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer May 7, 2024
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk NMIBC May 7, 2024
Positive Ph 2 Preliminary Data of SLS009 in R/R AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation at the Optimal Dose Level Announced May 7, 2024
Calquence combo regimen demonstrated statistically significant and clinically meaningful PFS improvement in 1L MCL in ECHO Ph 3 trial May 7, 2024
Ph 2 data for ERLEADA + ADT after radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than 2 years post-surgery May 7, 2024
Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk NMIBC Announced May 7, 2024
